Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

Pigment Cell and Melanoma Research

Volumn 28, Issue 3, 2015, Pages 318-323

  Hoogstraat, Marlous ^a,b   Gadellaa van Hooijdonk, Christa G ^a,b   Ubink, Inge ^a,b   Besselink, Nicolle J M ^a,b   Pieterse, Mark ^a   Veldhuis, Wouter ^a   van Stralen, Marijn ^c   Meijer, Eelco F J ^a   Willems, Stefan M ^a,b   Hadders, Michael A ^a   Kuilman, Thomas ^d   Krijgsman, Oscar ^d   Peeper, Daniel S ^d   Koudijs, Marco J ^a,b   Cuppen, Edwin ^a,b   Voest, Emile E ^a,b   Lolkema, Martijn P ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Netherlands Center for Personalized Cancer Treatment   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

BRAF; Intratumoral heterogeneity; Therapy resistance; Vemurafenib; Volumetric imaging analysis

Indexed keywords

B RAF KINASE; DNA; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; DNA SEQUENCE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; IMAGE ANALYSIS; METASTATIC MELANOMA; NEXT GENERATION SEQUENCING; PROGRESSION FREE SURVIVAL; THREE DIMENSIONAL IMAGING; BIOPSY; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MELANOMA; METASTASIS; MUTATION; PATHOLOGY;

BIOPSY; DIAGNOSTIC IMAGING; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; INDOLES; MELANOMA; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84927042705     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12347     Document Type: Article

References (33)

1. Antonescu, C.R., Besmer, P., Guo, T. et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 11, 4182-4190.
2. Balak, M.N., Gong, Y., Riely, G.J. et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501.
3. Campbell, P.J., Yachida, S., Mudie, L.J. et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113.
4. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
5. Choi, J., Landrette, S.F., Wang, T. et al. (2014). Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 27, 253-262.
6. Ding, L., Ley, T.J., Larson, D.E. et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510.
7. Eisenhauer, E.A., Therasse, P., Bogaerts, J. et al. (2008). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247.
8. Emery, C.M.C., Vijayendran, K.G.K., Zipser, M.C.M. et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416.
9. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004). A census of human cancer genes. Audio Electroacoust. Newslett. IEEE4, 177-183.
10. Gerlinger, M., Rowan, A.J., Horswell, S. et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892.
11. Greger, J.G.J., Eastman, S.D.S., Zhang, V.V., Bleam, M.R.M., Hughes, A.M.A., Smitheman, K.N.K., Dickerson, S.H.S., Laquerre, S.G.S., Liu, L.L., and Gilmer, T.M.T. (2012). Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920.
12. Joseph, E.W.E., Pratilas, C.A.C., Poulikakos, P.I.P. et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908.
13. van Kessel, C.S.C., Van Leeuwen, M.S.M., Witteveen, P.O.P., Kwee, T.C.T., Verkooijen, H.M.H., and van Hillegersberg, R.R. (2012). Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy. Eur. J. Radiol. 81, 2543-2549.
14. Lito, P., Rosen, N., and Solit, D.B. (2013). Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409.
15. Mao, M.M., Tian, F.F., Mariadason, J.M.J. et al. (2013). Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19, 657-667.
16. Menzies, A.M., Haydu, L.E., Carlino, M.S., Azer, M.W.F., Carr, P.J.A., Kefford, R.F., and Long, G.V. (2014). Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS ONE 9, e85004.
17. Nazarian, R.R., Shi, H.H., Wang, Q.Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
18. Nishida, T., Kanda, T., Nishitani, A., Takahashi, T., Nakajima, K., Ishikawa, T., and Hirota, S. (2008). Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 99, 799-804.
19. Rizos, H., Menzies, A.M., Pupo, G.M. et al. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965-1977.
20. Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D., Peters, S., Rimoldi, D., and Michielin, O. (2013). Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin. Cancer Res. 19, 5749-5757.
21. Schiavon, G., Ruggiero, A., Schöffski, P., van der Holt, B., Bekers, D.J., Eechoute, K., Vandecaveye, V., Krestin, G.P., Verweij, J., Sleijfer, S., and Mathijssen, R.H.J. (2012). Tumor volume as an alternative response measurement for imatinib treated GIST patients. PLoS ONE 7, e48372.
22. Shi, H., Hugo, W., Kong, X. et al. (2014). Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93.
23. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
24. Stoecklein, N.H., and Klein, C.A. (2010). Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 126, 589-598.
25. Swoboda, A., Rasin-Streden, D., Schanab, O., Okamoto, I., Pehamberger, H., Petzelbauer, P., and Mikula, M. (2011). Identification of genetic disparity between primary and metastatic melanoma in human patients. Genes Chromosomes Cancer 50, 680-688.
26. Tirumani, S.H., Shinagare, A.B., Jagannathan, J.P., Krajewski, K.M., Ramaiya, N.H., and Raut, C.P. (2014). Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur. J. Surg. Oncol. 40, 420-428.
27. Trunzer, K., Pavlick, A.C., Schuchter, L. et al. (2013). Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767-1774.
28. Van Allen, E.M., Wagle, N., Sucker, A. et al. (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109.
29. Vermaat, J.S., Nijman, I.J., Koudijs, M.J. et al. (2012). Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin. Cancer Res. 18, 688-699.
30. Wagenaar, T.R., Ma, L., Roscoe, B., Park, S.M., Bolon, D.N., and Green, M.R. (2014). Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res. 27, 124-133.
31. Wagle, N., Van Allen, E.M., Treacy, D.J. et al. (2014). MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68.
32. Whittaker, S.R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G.S., Schadendorf, D., Root, D.E., and Garraway, L.A. (2013). A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362.
33. Yang, H.H., Higgins, B.B., Kolinsky, K.K. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.